Citations

Clear

9383 citation(s) found for "Thomas, PS".

Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
Marcucci, Guido , Metzeler, Klaus H. , Schwind, Sebastian , Becker, Heiko , Maharry, Kati , Mrózek, Krzysztof , Radmacher, Michael D., Kohlschmidt, Jessica, Whitman, Susan P., Wu, Yue-Zhong, Powell, Bayard L., Carter, Thomas H. , Kolitz, Jonathan E. , Wetzler, Meir , Carroll, Andrew J. , Baer, Maria R. , Moore, Joseph O. , Larson, Richard A. , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Journal of Clinical Oncology | January 31, 2012 | Volume: 30 | Issue: 7 | Pages: 742-750

10.1200/jco.2011.39.2092 | PMID 22291079 Get It

Purpose To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML). Patients and Methods Four hundred fifteen previously untreated adults were analyzed for DNMT3A mutations and established prognostic gene mutations and expression markers. Gene- and microRNA-expression profiles were derived using microarrays. Results Younger (< 60 years; n = 181) and older (≥ 60 years; n = 234) patients had similar frequencies of DNMT3A mutations (35.3% v 33.3%). Missense mutations affecting arginine codon 882 (R882-DNMT3A) were more common (n = 92; 62%) than those affecting other codons (non–R882-DNMT3A). DNMT3A-mutated patients did not differ regarding complete remission rate, but had shorter disease-free survival (DFS; P = .03) and, by trend, overall survival (OS; P = .07) than DNMT3A–wild-type patients. In multivariable analyses, DNMT3A mutations remained associated with shorter DFS (P = .01), but not with shorter OS. When analyzed separately, the two DNMT3A mutation types had different significance by age group. Younger patients with non–R882-DNMT3A mutations had shorter DFS (P = .002) and OS (P = .02), whereas older patients with R882-DNMT3A mutations had shorter DFS (P = .005) and OS (P = .002) after adjustment for other clinical and molecular prognosticators. Gene- and microRNA-expression signatures did not accurately predict DNMT3A mutational status. Conclusion DNMT3A mutations are frequent in CN-AML, and their clinical significance seems to be age dependent. DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non–R882-DNMT3A mutations are associated with adverse prognosis in younger patients. Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated.
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Pasquinelli, C, McPhee, Fiona, Eley, Timothy, Villegas, Criselda, Sandy, Katrina, Sheridan, Pamela L., Persson, Anna , Huang, Shu-Pang, Hernandez, Dennis , Sheaffer, Amy K. , Scola, Paul M. , Marbury, Thomas , Goldwater, Ronald, Rodríguez‐Torres, M., DeMicco, Michael, Wright, David W. , Kraft, Walter K. , Lopez-Talavera, Juan-Carlos, Grasela, Dennis M., Lawitz, Eric , Charlton, Michael

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 31, 2012 | Volume: 56 | Issue: 4 | Pages: 1838-1844

10.1128/aac.05854-11 | PMID 22290978 Get It

ABSTRACT Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.
Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation
Carey, Elizabeth J. , Aqel, Bashar , Byrne, Thomas , Douglas, David D., Rakela, Jorge , Vargas, Hugo E. , Moss, Adyr A. , Reddy, Kunam S. , Chakkera, Harini A. , Aqel, Bashar A. , Mulligan, David C. , Vargas, Hugo E , Chakkera, Harini A

Mayo Clinic

Journal of Transplantation | January 29, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/614781 | PMID 22461975 Get It

New-onset diabetes after transplantation (NODAT) is common after liver transplant and associated with poorer outcomes. The aim of this study was to identify risk factors for NODAT in liver transplant recipients off corticosteroids. In 225 adult nondiabetic liver transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation, 17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were significant. Each 10 mg/dL increase in pretransplant FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in patients off corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.
Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure
Hellkamp, Anne S., Hernandez, Adrian F. , Fonarow, Gregg C. , Thomas, Kevin L. , Al‐Khalidi, Hussein R. , Heidenreich, Paul A. , Hammill, Stephen C., Al‐Khatib, Sana M. , Yancy, Clyde W. , Peterson, Eric D. , Hernandez, Adrian

Mayo Clinic

Circulation | January 28, 2012 | Volume: 125 | Issue: 9 | Pages: 1094-1101

10.1161/circulationaha.111.066605 | PMID 22287589 Get It

Background— Prior studies have demonstrated low use of implantable cardioverter defibrillators (ICDs) as primary prevention, particularly among women and blacks. The degree to which the overall use of ICD therapy and disparities in use have changed is unclear. Methods and Results— We examined 11 880 unique patients with a history of heart failure and left ventricular ejection fraction ≤35% who were ≥65 years old and enrolled in the Get With the Guidelines–Heart Failure (GWTG-HF) program from January 2005 through December 2009. We determined the rate of ICD use by year for the overall population and for sex and race groups. From 2005 to 2007, overall ICD use increased from 30.2% to 42.4% and then remained unchanged in 2008 to 2009. After adjustment for potential confounders, ICD use increased significantly in the overall study population during 2005 to 2007 (odds ratio, 1.28; 95% confidence interval, 1.11–1.48 per year; P =0.0008) and in black women (odds ratio, 1.82; 95% confidence interval, 1.28–2.58 per year; P =0.0008), white women (odds ratio, 1.30; 95% confidence interval, 1.06–1.59 per year; P =0.010), black men (odds ratio, 1.54; 95% confidence interval, 1.19–1.99 per year; P =0.0009), and white men (odds ratio, 1.25; 95% confidence interval, 1.06–1.48 per year; P =0.0072). The increase in ICD use was greatest among blacks. Conclusions— In the GWTG-HF quality improvement program, a significant increase in ICD therapy use was observed over time in all sex and race groups. The previously described racial disparities in ICD use were no longer present by the end of the study period; however, sex differences persisted.
Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants
White, Kristin L., Schildkraut, Joellen M. , Palmieri, Rachel T., Iversen, Edwin S., Vierkant, Robert A. , Rider, David N., Charbonneau, Bridget, Cicek, Mine S., Sutphen, Rebecca , Birrer, Michael J. , Song, Honglin , Gayther, Simon A. , Ramus, Susan J. , Wentzensen, Nicolas , García‐Closas, Montserrat , Phelan, Catherine M., Cunningham, Julie M. , Sellers, Thomas A. , Goode, Ellen L. , Weber, Rachel Palmieri , Berchuck, Andrew , Pharoah, Paul D.P. , Tyrer, Jonathan P. , Yang, Hannah , Fridley, Brooke L. , Ramus, Susan J , Vierkant, Robert A , García-Closas, Montserrat

Mayo Clinic

Cancer Research | January 26, 2012 | Volume: 72 | Issue: 5 | Pages: 1064-1069

10.1158/0008-5472.can-11-3512 | PMID 22282663 Get It

Abstract The importance of inflammation pathways to the development of many human cancers prompted us to examine the associations between single-nucleotide polymorphisms (SNP) in inflammation-related genes and risk of ovarian cancer. In a multisite case–control study, we genotyped SNPs in a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using a custom array and analyzed by logistic regression. SNPs with P &lt; 0.10 were evaluated among 3,143 cases and 2,102 controls from the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) post-GWAS collaboration. Combined analysis revealed association with SNPs rs17561 and rs4848300 in the interleukin gene IL1A which varied by histologic subtype (Pheterogeneity = 0.03). For example, IL1A rs17561, which correlates with numerous inflammatory phenotypes, was associated with decreased risk of clear cell, mucinous, and endometrioid subtype, but not with the most common serous subtype. Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated with decreased risk. Thus, inherited variation in IL1A and ALOX5 seems to affect ovarian cancer risk which, for IL1A, is limited to rarer subtypes. Given the importance of inflammation in tumorigenesis and growing evidence of subtype-specific features in ovarian cancer, functional investigations will be important to help clarify the importance of inherited variation related to inflammation in ovarian carcinogenesis. Cancer Res; 72(5); 1064–9. ©2012 AACR.
Developing a Preoperative Briefing Protocol for Cardiovascular Surgery
Suther, Thomas, Wiegmann, Douglas A. , Henrickson, Sarah Emily

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | January 19, 2012 | Volume: 51 | Issue: 11 | Pages: 712-716

10.1177/154193120705101123 Get It

Objective: Design a protocol for conducting preoperative briefings within the context of cardiovascular surgery. Method: A combined questionnaire and semi-structured focus group approach involving four subspecialties of surgical staff (n = 47) was conducted to gather information concerning (1) attitudes towards preoperative briefings, (2) logistical issues related to the conduct and content of briefings and (3) potential barriers that might impede implementation. Results: Analyses revealed consensus among surgical staff concerning briefing benefits (majority were very positive), duration (< 10 min), location (in the OR), content (procedure, patient, and equipment issues) and potential barriers (staff availability, attitudes, case scheduling, and lack of resources). Differences in opinions arose concerning timing of the brief (e.g., before vs. after patient enters OR) and the role of key participants. Discussion: A prototype checklist for conducting preoperative briefings was developed based on these results. Additional research is needed to implement and validate its effectiveness.
A Human Factors Analysis of Cardiopulmonary Bypass Machines and Associated Components and Procedures
Suther, Thomas, Wiegmann, Douglas A. , Sundt, Thoralf M. , Phillips, Brent R.

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | January 19, 2012 | Volume: 50 | Issue: 17 | Pages: 1897-1900

10.1177/154193120605001738 Get It

Cardiopulmonary bypass machines (CBM's), first developed in 1953, are commonly used during heart surgery to oxygenate blood and circulate it throughout the body while the heart is stopped. Although several advances have occurred in the engineering of perfusion pumps, the interface design of CBM's has not changed appreciably for several decades. The growing awareness of human error in medicine has highlighted the role that poorly designed medical devices can play in producing errors that cause patient harm. The purpose of this study, therefore, was to identify issues related to CBM design that may predispose surgical teams to make errors. The study utilized multiple research methods including observations, heuristic evaluations, structured interviews and usability assessments. Results revealed several fundamental design problems associated CBM displays, controls, alarms, and component integration, as well as communication and procedural issues. These data provide valuable information for redesigning CBM's to reduce errors and improve patient safety.
Partial Pathologic Response and Nodal Status as Most Significant Prognostic Factors for Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy
Huebner, Marianne , Wolff, Bruce G., Smyrk, Thomas C. , Aakre, Jeremiah A. , Larson, David W.

Mayo Clinic

World Journal of Surgery | January 19, 2012 | Volume: 36 | Issue: 3 | Pages: 675-683

10.1007/s00268-011-1409-8 | PMID 22270980 Get It

AbstractBackgroundThis study evaluated the impact of tumor regression grading (TRG) and other pathologic variates in a cohort of rectal carcinoma patients treated with neoadjuvant chemoradiotherapy (CRT). The value of a grading less than pCR for predicting survival is unknown. Tumor budding has not been systematically studied in rectal cancer after neoadjuvant therapy.MethodsPathologic risk factors for survival were evaluated on surgical specimens of 237 patients with stages I, II, and III rectal cancer treated between 1996 and 2006. All patients underwent preoperative CRT followed by surgical resection 6–8 weeks later. TRG, tumor grade, budding, venous invasion, radial margin, and nodal status were evaluated. The prognostic value of TRG categories was calculated with Cox regression models and validated with resampling methods.ResultsTRG of <25% occurred in 61 (25.7%) and a complete response in 39 (16.4%) of the resected specimens. TRG of <25% was shown to be a statistically significant predictor for cancer‐specific survival (CSS) and recurrence‐free survival (RFS) compared to TRG ≥25% (P = 0.013). Tumor budding was present in 24 (10.1%) of the patients and was negatively associated with CSS (P = 0.013). Lymph node involvement was observed in 83 (35.0%) patients. TRG and nodal status (P < 0.001) were the most significant predictors associated with outcome.ConclusionPartial pathologic response ≥25% was a superior predictor compared to pCR for improved survival after preoperative CRT. CSS and RFS were adversely affected by the presence of lymph node metastases.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Phelps, Creighton H., Beach, Thomas G. , Bigio, Eileen H. , Cairns, Nigel J. , Carrillo, María C. , Dickson, Dennis W. , Duyckaerts, Charles , Frosch, Matthew P. , Masliah, Eliezer , Mirra, Suzanne S., Nelson, Peter T. , Thal, Dietmar Rudolf , Thies, Bill, Trojanowski, John Q. , Vinters, Harry V. , Montine, Thomas J. , Hyman, Bradley T. , Schneider, Julie A. , Dickson, Dennis W , Thal, Dietmar Rudolf

Mayo Clinic

Alzheimer's & Dementia | January 19, 2012 | Volume: 8 | Issue: 1 | Pages: 1-13

10.1016/j.jalz.2011.10.007 | PMID 22265587 Get It

Abstract A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
Candidate Serum Biomarkers for Prostate Adenocarcinoma Identified by mRNA Differences in Prostate Tissue and Verified with Protein Measurements in Tissue and Blood
Klee, Eric W. , Bondar, Olga P., Goodmanson, Marcia K., Dyer, Roy B. , Erdoğan, Sibel , Bergstralh, Eric J., H., Robert Bergen, Sebo, Thomas J., Klee, George G.

Mayo Clinic

Clinical Chemistry | January 13, 2012 | Volume: 58 | Issue: 3 | Pages: 599-609

10.1373/clinchem.2011.171637 | PMID 22247499 Get It

Abstract BACKGROUND Improved tests are needed for detection and management of prostate cancer. We hypothesized that differential gene expression in prostate tissue could help identify candidate blood biomarkers for prostate cancer and that blood from men with advanced prostate disease could be used to verify the biomarkers presence in circulation. METHODS We identified candidate markers using mRNA expression patterns from laser-capture microdissected prostate tissue and confirmed tissue expression using immunohistochemistry (IHC) for the subset of candidates having commercial antisera. We analyzed tissue extracts with tandem mass spectrometry (MS/MS) and measured blood concentrations using immunoassays and MS/MS of trypsin-digested, immunoextracted peptides. RESULTS We selected 35 novel candidate prostate adenocarcinoma biomarkers. For all 13 markers having commercial antisera for IHC, tissue expression was confirmed; 6 showed statistical discrimination between nondiseased and malignant tissue, and only 5 were detected in tissue extracts by MS/MS. Sixteen of the 35 candidate markers were successfully assayed in blood. Four of 8 biomarkers measured by ELISA and 3 of 10 measured by targeted MS showed statistically significant increases in blood concentrations of advanced prostate cancer cases, compared with controls. CONCLUSIONS Seven novel biomarkers identified by gene expression profiles in prostate tissue were shown to have statistically significant increased concentrations in blood from men with advanced prostate adenocarcinoma compared with controls: apolipoprotein C1, asporin, cartilage oligomeric matrix protein, chemokine (C-X-C motif) ligand 11 (CXCL11), CXCL9, coagulation factor V, and proprotein convertase subtilisin/kexin 6.